RSS
Consumer News
Consumer Reports
Trusted reliable news sources from around the web. We offer special news reports, topic news videos, and related content stories. Truly a birds eye view on news.
Consumer Resources
- Details
- Written by Bing News Search Results
- Category: Vehicle News Articles
Cheap electric cars thrive in Europe and China, but North America’s regulations, roads and obsession with bigger vehicles have left the affordable EV behind.The Latest Tech News, Delivered to Your Inb ...
Original Image Link
Source:www.msn.com
Original Image Link
Source:www.msn.com
- Details
- Written by CNET Reviews
- Category: Reviews
Save up to $150: You can never have too much extra storage, and right now you can grab a full terabyte at a great price. Amazon just dropped the 1TB Verbatim Pocket SSD down to $150, which saves you a whopping 50%. That’s a serious discount and drops this portable SSD down to a new…
Photo By CNET
Photo By CNET
- Details
- Written by CNET Reviews
- Category: Reviews
It’s easy to forget that 3D printing is more than just flexi-dragons and keychains. At home, 3D printing lets us create fun and interesting things, but it’s also a serious manufacturing tool. In my reviews, I spend a lot of time testing 3D printers’ ability to produce high-quality prints that you would be proud to…
Photo By CNET
Photo By CNET
- Details
- Written by CNET Reviews
- Category: Reviews
Save $20: Right now, this seven-in-one Anker Nano charging station is down to $60 at Amazon, saving you $20 off its typical price. This is just $3 more than its lowest-ever price and still a solid deal. Frugal shoppers trying to fight clutter can also nab a charger for the same price at Best Buy.
Photo By CNET
Photo By CNET
- Details
- Written by CNET Reviews
- Category: Reviews
ChatGPT is the most well-known AI chatbot around, but Gemini has been gaining popularity for the past few years. Both models are great with text, but we’re in a multimodal world now, and using your camera to help AI identify objects is becoming increasingly common.
Photo By CNET
Photo By CNET
- Details
- Written by Consumer Affairs News
- Category: Consumer Daily Reports
Roches new blood test can help doctors assess whether amyloid pathology linked to Alzheimers disease is likely present.
The test is intended for people 55 and older who have signs, symptoms, or concerns about cognitive decline.
Because it can be used in both primary and specialty care, the test could make the evaluation process more accessible for some patients.
Getting answers about changes in memory or thinking can involve a number of steps, particularly when doctors are trying to determine whether Alzheimers disease may be involved.
Now, the U.S. Food and Drug Administration (FDA) has cleared a new blood test from Roche that could give doctors another tool for that process.
The Elecsys pTau217 blood test is designed to help assess amyloid pathology associated with Alzheimers disease. Roche says it is the first and only FDA-cleared single-biomarker blood test that can support both ruling in and ruling out amyloid pathology in primary and specialty care settings.
"FDA clearance of Elecsys pTau217 marks an important milestone in Alzheimer's disease diagnosis and underscores Roche's continued leadership in advancing innovative solutions that can help patients get answers sooner," Dan Malarek, President and CEO of Roche Diagnostics North America, said in a news release.
"As the first and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology, Elecsys pTau217 has the potential to transform how Alzheimer's is assessed across primary and specialty care. This kind of innovation can help bring diagnostic evaluation closer to patients and give clinicians greater confidence in determining the right step in their care.
How the test works
The test measures phosphorylated tau 217, or pTau217, in a blood sample. Rather than producing a simple yes-or-no diagnosis, the test provides positive, intermediate, or negative results indicating the likelihood of amyloid pathology.
Those results aren't meant to stand alone. Doctors are expected to consider them alongside a patient's clinical information and other relevant findings when determining the next steps in an Alzheimer's evaluation.
The test is intended for people aged 55 and older who have signs, symptoms, or complaints of cognitive decline.
Consumer Daily Reports Article Count: 6212
Environmental News Articles Article Count: 43
Reviews Article Count: 2436
Vehicle News Articles Article Count: 754
Related Product Search/Búsqueda de productos relacionados
